Ro7568282

Phase 2

Roche

Ro7568282 is one of 70 therapeutic programs targeting Parkinson's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Parkinson's DiseaseNot yet recruiting

Alzheimer's DiseaseNot yet recruiting

Parkinson's DiseasePreclinical

Not yet recruiting

Alzheimer's DiseasePhase 2

Not yet recruiting

Competition

Competitive Landscape

59 competitors in Alzheimer's Disease

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

31 2

Leqembi

Eisai

Phase 3

7 3

Nuplazid

AACADIA Pharmaceuticals Inc.

Ozempic

3 5

Qalsody

Biogen

Phase 3

1 6

Namenda

AbbVie

Phase 2

2 7

Briviact

UCB

Phase 2

1 8

Leukine

Sanofi

Phase 2

1 9

Niacor

AbbVie

Phase 2

1 10

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Not yet recruiting

Alzheimer's Disease

NCT07781657

Q2 2032

PreclinicalNot yet recruiting

Parkinson's Disease

NCT07781644

Clinical

Trials by Indication[1]

Alzheimer's Disease1 trial

A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of RO7568282 in Participants With Early Symptomatic Alzheimer's Disease

Not yet recruiting· Roche logo

Roche·Phase 2·NCT07781657·450 enrolled

Parkinson's Disease1 trial

A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of RO7568282 in Participants With Early-stage Parkinson's Disease

Not yet recruiting· Roche logo

Roche·Preclinical·NCT07781644·474 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ro7568282. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ro7568282. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Roche

Ro7568282

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Q2 2032

Trials by Indication[1]

Alzheimer's Disease1 trial

Parkinson's Disease1 trial

References

Drug Info

Quick Facts

Related News